Valeant set to expand in Australia/Asia Pacific markets with iNova acquisition
This article was originally published in Scrip
Continuing its buying spree, Valeant Pharmaceuticals is now set to strengthen its presence in the Australian and Asia Pacific markets having agreed to acquire iNova, a private pharmaceutical group which sells and distributes prescription and over-the-counter (OTC) products in Australia, New Zealand, Southeast Asia and South Africa. Valeant is buying the firm from Australian private equity firms, Archer Capital and Ironbridge and other minority management shareholders.
You may also be interested in...
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.